Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05624606 · ClinicalTrials.gov registry record · Phase 1
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adult Participants 18 Years of Age and Older
A Phase 1 study, sponsored by Sanofi Pasteur, a Sanofi Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 682
- Enrollment target
NCT05624606 is a Phase 1 study that has completed, run by Sanofi Pasteur, a Sanofi Company. The registered enrollment target is 682 participants.
The verdict
NCT05624606, a Phase 1 study, has completed, sponsored by Sanofi Pasteur, a Sanofi Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 682 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and immunogenicity of a single intramuscular (IM) injection of up to 3 dose levels of Quadrivalent Influenza mRNA Vaccine MRT5410 compared to an active control (QIV SD, QIV HD \[adults ≥ 65 years of age only\], or RIV4) in adults 18 years of age and older.
Interventions
- BIOLOGICAL Quadrivalent Influenza mRNA Vaccine MRT5410
- BIOLOGICAL Quadrivalent Recombinant Influenza vaccine RIV4
- BIOLOGICAL Quadrivalent Inactivated Influenza Standard Dose QIV-SD
- BIOLOGICAL Quadrivalent Inactivated Influenza High Dose QIV-HD
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 682 participants |
| Start Date | 2022-11-28 |
| Est. Completion | 2024-03-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05624606
The ClinicalTrials.gov registry entry for NCT05624606 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 682 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi Pasteur, a Sanofi Company, which has 153 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Quadrivalent Influenza mRNA Vaccine MRT5410 is the first listed.
NCT05624606 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05624606 about?
NCT05624606 is a clinical study titled "Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adult Participants 18 Years of Age and Older". The purpose of this study is to evaluate the safety and immunogenicity of a single intramuscular (IM) injection of up to 3 dose levels of Quadrivalent Influenza mRNA Vaccine MRT5410 compared to an active control (QIV SD, QIV HD \[adults ≥ 65 years of age only\], or RIV4) in adults 18 years of age an...
What is the current status of trial NCT05624606?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 682 participants. The study started on 2022-11-28. Estimated completion is 2024-03-28.
What interventions are being tested in trial NCT05624606?
The interventions under investigation include: Quadrivalent Influenza mRNA Vaccine MRT5410 (BIOLOGICAL), Quadrivalent Recombinant Influenza vaccine RIV4 (BIOLOGICAL), Quadrivalent Inactivated Influenza Standard Dose QIV-SD (BIOLOGICAL), Quadrivalent Inactivated Influenza High Dose QIV-HD (BIOLOGICAL).
Who is sponsoring clinical trial NCT05624606?
This trial is sponsored by Sanofi Pasteur, a Sanofi Company, which has 153 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.